etazolate   Click here for help

GtoPdb Ligand ID: 7336

Synonyms: EHT-0202 | SQ 20009
Compound class: Synthetic organic
Comment: Has anxiolytic effects as positive allosteric modulator of the GABAA receptor at the barbiturate binding site, as an adenosine antagonist of the A1 and A2 receptor subtypes and as a phosphodiesterase inhibitor selective for the PDE4 isoform. It is currently in clinical trials for the treatment of Alzheimer's disease with a possible MMOA of upregulating alpha-secretase activity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 81.4
Molecular weight 289.15
XLogP 3.43
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCOC(=O)c1cnc2c(c1NN=C(C)C)cnn2CC
Isomeric SMILES CCOC(=O)c1cnc2c(c1NN=C(C)C)cnn2CC
InChI InChI=1S/C14H19N5O2/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2/h7-8H,5-6H2,1-4H3,(H,15,18)
No information available.
Summary of Clinical Use Click here for help
A range of clinical and animal model effects have been reported for etazolate mainly related to antidepressant-like effects (see the PubMed title matches) but this entry picks up the Alzheimers's indication. A Phase 2a study was completed in 2011 [2]